| Inhibitory effect of angiotensin Ⅱ receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis |
| |
| 引用本文： | Yokohama S,Tokusashi Y,Nakamura K,Tamaki Y,Okamoto S,Okada M,Aso K,Hasegawa T,Aoshima M,Miyokawa N,Haneda M,Yoneda M. Inhibitory effect of angiotensin Ⅱ receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis[J]. World journal of gastroenterology : WJG, 2006, 12(2): 322-326. DOI: 10.3748/wjg.v12.i2.322 |
| |
| 作者姓名： | Yokohama S Tokusashi Y Nakamura K Tamaki Y Okamoto S Okada M Aso K Hasegawa T Aoshima M Miyokawa N Haneda M Yoneda M |
| |
| 摘 要： |
|
| 关 键 词： | NASH NAFLD 肝纤维化 HSC 血管紧张素 |
| 收稿时间： | 2005-05-31 |
Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis |
| |
| Yokohama Shiro,Tokusashi Yoshihiko,Nakamura Kimihide,Tamaki Yosui,Okamoto Satoshi,Okada Mituyoshi,Aso Kazunobu,Hasegawa Takenao,Aoshima Masaru,Miyokawa Naoyuki,Haneda Masakazu,Yoneda Masashi. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis[J]. World journal of gastroenterology : WJG, 2006, 12(2): 322-326. DOI: 10.3748/wjg.v12.i2.322 |
| |
| Authors: | Yokohama Shiro Tokusashi Yoshihiko Nakamura Kimihide Tamaki Yosui Okamoto Satoshi Okada Mituyoshi Aso Kazunobu Hasegawa Takenao Aoshima Masaru Miyokawa Naoyuki Haneda Masakazu Yoneda Masashi |
| |
| Affiliation: | Second Department of Medicine, Asahikawa Medical College, Midorigaoka higashi 2-1-1-1, Asahikawa 078-8510, Japan. yokohama@reha.or.jp |
| |
| Abstract: | AIM: To investigate the efficacy of angiotensin II receptor antagonist on hepatic stellate cells (HSCs) activation in the patients with non-alcoholic steatohepatitis (NASH). METHODS: Seven patients with NASH were prescribed losartan, a selective angiotensin II type 1 receptor antagonist (50 mg/d) for 48 wk. Liver biopsies were performed both at the entry and end of the study in all patients. Quiescent and activated HSCs were identified by double immunostaining using anti-p75 and -smooth muscle actin antibodies, and the number of each phenotype was counted. Similarly, the liver specimens obtained from the eight patients with non-alcoholic fatty liver (NAFL) were also examined as controls. RESULTS: In NASH hepatic tissues, activated HSCs were dominantly distributed as compared with those in NAFL. The 48-wk losartan treatment induced a remarkable decrease in activated HSCs and a mild increase in quiescent phenotypes. CONCLUSION: Our data suggest the crucial involvement of HSCs in anti-fibrotic effect of angiotensin II receptor antagonist on patients with NASH. |
| |
| Keywords: | NASH NAFLD Hepatic fibrosis HSC Losartan |
| 本文献已被 维普 PubMed 等数据库收录！ |
|
